Bicycle Therapeutics plc, a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, announced the poster presentation of two… read more.
Merck, a leading science and technology company, announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology… read more.
BeiGene, Ltd., a global oncology company that will change its name to BeOne Medicines Ltd., announced it will share 23 abstracts featuring new data across its hematology and solid… read more.
Astellas Pharma Incwill present 16 abstracts featuring new data across its approved cancer therapies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 –… read more.
Eisai Co., Ltd. announced the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO25), which… read more.
AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical… read more.
Innate Pharma SA announced that four abstracts with Innate’s drugs in clinical development have been accepted for the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking… read more.
Gilead Sciences, Inc. (will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting May 30 –… read more.
Shockwave Medical, Inc., part of Johnson & Johnson MedTech and a global leader in the field of circulatory restoration, announced that data from 23 company-sp onsored and funded studies, including… read more.
2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2025 Congress. “The breadth of our oncology and hematology portfolio – anchored by… read more.
Nurix Therapeutics, Inc. announced that data from the Company’s ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia… read more.
BridgeBio Pharma, Inc. a new type of biopharmaceutical company focused on genetic diseases, announced that one rapid-fire abstract and two moderated ePosters on the clinical outcomes and quality… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
